[Clinical experience with Arwin (author's transl)].
Treatment of 52 cases with Arwin is reported. Convincing success was achieved in disorders of peripheral arterial blood flow in stage III (pain at rest), in which more than 80% of the patients treated became free from pain. In stage IV the success rate is barely 50%. A combination of thrombolysis with streptokinase and Arwin instead of heparin proved valuable as a primary approach in poor outflow conditions. In 4 out of 5 successful second lyses after reobliteration the vascular system remained patent under Arwin.
D000328:Adult; D000721:Ancrod / Q000009:adverse effects / Q000627:therapeutic use*; D001157:Arterial Occlusive Diseases / Q000188:drug therapy*; D001775:Blood Circulation / Q000187:drug effects; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D010450:Endopeptidases / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D012075:Remission, Spontaneous; D013300:Streptokinase / Q000627:therapeutic use; D013923:Thromboembolism / Q000188:drug therapy
D010450:Endopeptidases; D013300:Streptokinase; D000721:Ancrod
Klinische Erfahrungen mit Arwin